{"schema_version":"secwatch.filing_event.v1","accession":"0001558370-21-015398","form_type":"8-K","ticker":"MGTX","cik":"0001735438","company_name":"MeiraGTx Holdings plc","filed_at":"2021-11-10T23:59:59+00:00","discovered_at":"2026-05-14T18:04:13.885749+00:00","generated_at":"2026-06-28T10:04:45.995546+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"MeiraGTx Q3 net loss $25.9M ($0.59/sh); cash $143.6M; R&D spend jumps","bullets":["Net loss $25.9M ($0.59 loss per share) vs $6.4M ($0.17) YoY; license revenue $6.9M.","R&D expenses surged to $21.6M from $4.6M on clinical trial and manufacturing costs.","Cash and equivalents $143.6M; expects funding into Q2 2023.","Phase 3 Lumeos trial for XLRP screening; AQUAx xerostomia Phase 1 enrollment to complete Q4 2021.","IND planned for AAV-GAD in Parkinson's and Phase 3 pivotal trial for AAV-RPE65 in early 2022."],"urls":{"canonical":"https://secwatch.observer/filing/0001558370-21-015398","json":"https://secwatch.observer/filing/0001558370-21-015398.json","markdown":"https://secwatch.observer/filing/0001558370-21-015398.md","text":"https://secwatch.observer/filing/0001558370-21-015398.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1735438/000155837021015398/0001558370-21-015398-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1735438/000155837021015398/mgtx-20211110x8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-28T10:04:45.995546+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}